Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer

Inclusion Criteria: * Age \>18 * WHO performance status 0-2 * Life expectancy ≥ 3 months * Patients receiving androgen-suppressive therapy in the form of chirurgical castration by orchiectomy or pulpectomy,or medical by LHRH agonist or antagonist with or without anti-androgen or all treatment blocking non gonadic testosterone fraction * Resulting to testosteronemia \<0,5 ng/ml * Histologically confirmed adenocarcinomia of prostate cancer and documented hormone independant metastatic disease - defined by: objective progression with at least one measurable lesion and/or evaluable lesion according to RECIST criteria and /or a rise in PSA level ("rising PSA") * Total bilirubin ≤ upper limit of normal (ULN). * AST and ALT ≤ 1.5 times ULN. Alkaline phosphatase ≤ 2.5 times ULN. * Serum creatinine \< 140 µmol/L or creatinine clearance \> 60 mL/ min. * Neutrophil count \> 2.109 L-1. * Platelet count ≥ 100,000/mm3. * Hemoglobin ≥ 10 g/dL * Not previous chemotherapy, except Estracyt * No liver, kidney or heart failure link to treatment * No malabsorption syndrome or disease significantly affecting gastrointestinal function * Prior radiotherapies are permetted withing four weeks of the first study treatment and must be \< 25 % of the bone marrow, and all adverse events must be resolved * Prior surgery are permitted. Exclusion Criteria: * Age \< 18 * History of psychiatric disorders including psychotic disorder, dementia or seizures that would prohibit the understanding, observance and giving of informed consent * Previous or concomitant other malignancies except basal or squamous cell carcinoma of the skin or other cancer curatively treated with surgery and/or radiotherapy * Patients should not have symptomatic brain metastasis * Concurrent severe and/or uncontrolled co-morbid medical condition * Malabsorption syndrome or disease significantly affecting gastro-intestinal function or major resection of the stomach, proximal small bowel or grade \> 2 dysphagia * Patients with uncontrolled infection * History of significant neurologic (i.e. peripheral neuropathy grade \> 2 using NCI-CTC criteria v3.0) * Patients should not have received NSAIDs or COX2 inhibitors within the three weeks prior to starting the study * Treatment with any investigational drug within 30 days prior to registration * Patients should not have current regimen containing dietary phytonutrients